News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Eli Lilly and Company Osteoporosis Drug Forteo Regrows Jaw Bone, Early Studies Show
October 18, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BOSTON, Oct 16 (Reuters) - Eli Lilly and Co's (LLY.N) osteoporisis drug Forteo can regrow bone in jaws damaged by severe bone-destroying conditions called osteonecrosis and periodontitis, doctors reported on Saturday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase I
Eli Lilly and Company
MORE ON THIS TOPIC
Ovarian cancer
Corcept’s Ovarian Cancer Drug Hits ‘Robust’ Efficacy in Phase III, Setting Up Challenge to Merck, AbbVie
January 26, 2026
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Sanofi Stumbles Again in Eczema—But Plans FDA Filing for OX40 Blocker Anyway
January 23, 2026
·
2 min read
·
Tristan Manalac
Pain
Lexicon Opens Path to $1B+ Opportunity as FDA Greenlights Phase III for Non-Opioid Pill
January 22, 2026
·
2 min read
·
Tristan Manalac
Insights
From Sound Bites to Signals: Editors Parse Executive and Investor Chatter at JPM
January 22, 2026
·
1 min read
·
Jennifer Smith-Parker
